Teva Says Intas Unit Seeks Cancer Drug Generic Far Too Soon
Teva has hit a subsidiary of Intas Pharmaceuticals Ltd. with a patent suit in Delaware federal court, saying the unit filed too early to make and sell a generic version of...To view the full article, register now.
Already a subscriber? Click here to view full article